Menu Search
Equities

OptiBiotix Health PLC

OPTI:LSE

OptiBiotix Health PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)10.82
  • Today's Change-1.43 / -11.66%
  • Shares traded461.14k
  • 1 Year change-59.54%
  • Beta2.2358
Data delayed at least 20 minutes, as of Nov 22 2024 11:51 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year OptiBiotix Health PLC had net income fall from a gain of 2.59m to a loss of 2.04m despite a 40.92% increase in revenues from 457.00k to 644.00k. An increase in the cost of goods sold as a percentage of sales from 46.61% to 50.31% was a component in the falling net income despite rising revenues.
Gross margin47.98%
Net profit margin-524.43%
Operating margin-351.67%
Return on assets-33.25%
Return on equity-36.34%
Return on investment-34.85%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at OptiBiotix Health PLC fell by 417.00k. However, Cash Flow from Investing totalled 1.11m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 1.53m for operations while cash from financing was breakeven.
Cash flow per share-0.0297
Price/Cash flow per share--
Book value per share0.0752
Tangible book value per share0.0627
More ▼

Balance sheet in GBPView more

OptiBiotix Health PLC has little financial risk as the capital structure does not rely on leverage.
Current ratio6.18
Quick ratio5.36
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.